Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:founded |
2008
|
| gptkbp:headquarters_location |
gptkb:Tokyo
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kyowa Hakko Kirin
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
Nobuo Hanai
|
| gptkbp:notable_drug |
gptkb:Crysvita
gptkb:Gran gptkb:Poteligeo Nesp |
| gptkbp:numberOfEmployees |
over 5,000
|
| gptkbp:parentOrganization |
gptkb:Kirin_Holdings
|
| gptkbp:predecessor |
gptkb:Kyowa_Hakko_Kogyo
Kirin Pharma |
| gptkbp:products |
oncology drugs
biopharmaceuticals therapeutic antibodies immunology drugs nephrology drugs |
| gptkbp:researchInterest |
immunology
oncology nephrology central nervous system diseases |
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4151
|
| gptkbp:subsidiary |
Kyowa Kirin International
|
| gptkbp:website |
https://www.kyowakirin.com
|
| gptkbp:bfsParent |
gptkb:olopatadine
|
| gptkbp:bfsLayer |
6
|